PLASMA KALLIKREIN INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary ang...

Full description

Saved in:
Bibliographic Details
Main Authors Ogawa, Anthony Ken, Cheng, Alan C, Jabri, Salman, Wu, Zhicai, Bao, Jianming, Yang, Song, Zhao, Zhiqiang, Tian, Maoqun, Kuang, Rongze, Hicks, Jacqueline D, Hayes, Donna A. A. W, Sinz, Christopher J, Lang, Simon B, Shearn-Nance, Galen Paul
Format Patent
LanguageEnglish
Published 28.12.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
Bibliography:Application Number: US202118043357